Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME.
Infection-triggered disease onset, chronic immune activation and autonomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) point to an autoimmune disease directed against neurotransmitter receptors. We had observed elevated autoantibodies against ß2 adrenergic receptors,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5854315?pdf=render |
| _version_ | 1828338210691874816 |
|---|---|
| author | Carmen Scheibenbogen Madlen Loebel Helma Freitag Anne Krueger Sandra Bauer Michaela Antelmann Wolfram Doehner Nadja Scherbakov Harald Heidecke Petra Reinke Hans-Dieter Volk Patricia Grabowski |
| author_facet | Carmen Scheibenbogen Madlen Loebel Helma Freitag Anne Krueger Sandra Bauer Michaela Antelmann Wolfram Doehner Nadja Scherbakov Harald Heidecke Petra Reinke Hans-Dieter Volk Patricia Grabowski |
| author_sort | Carmen Scheibenbogen |
| collection | DOAJ |
| description | Infection-triggered disease onset, chronic immune activation and autonomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) point to an autoimmune disease directed against neurotransmitter receptors. We had observed elevated autoantibodies against ß2 adrenergic receptors, and muscarinic 3 and 4 acetylcholine receptors in a subset of patients. Immunoadsorption (IA) was shown to be effective in removing autoantibodies and improve outcome in various autoimmune diseases.10 patients with post-infectious CFS/ME and elevated ß2 autoantibodies were treated with IA with an IgG-binding column for 5 days. We assessed severity of symptoms as outcome parameter by disease specific scores. Antibodies were determined by ELISA and B cell phenotype by flow cytometry.IgG levels dropped to median 0.73 g/l (normal 7-16 g/l) after the 4th cycle of IA, while IgA and IgM levels remained unchanged. Similarly, elevated ß2 IgG antibodies rapidly decreased during IA in 9 of 10 patients. Also 6 months later ß2 autoantibodies were significantly lower compared to pretreatment. Frequency of memory B cells significantly decreased and frequency of plasma cells increased after the 4th IA cycle. A rapid improvement of symptoms was reported by 7 patients during the IA. 3 of these patients had long lasting moderate to marked improvement for 6-12+ months, 2 patients had short improvement only and 2 patients improved for several months following initial worsening.IA can remove autoantibodies against ß2 adrenergic receptor and lead to clinical improvement. B cell phenotyping provides evidence for an effect of IA on memory B cell development. Data from our pilot trial warrants further studies in CFS/ME. |
| first_indexed | 2024-04-13T22:24:37Z |
| format | Article |
| id | doaj.art-4a6932c1ecf049088cb3676adad1afd4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T22:24:37Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-4a6932c1ecf049088cb3676adad1afd42022-12-22T02:27:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019367210.1371/journal.pone.0193672Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME.Carmen ScheibenbogenMadlen LoebelHelma FreitagAnne KruegerSandra BauerMichaela AntelmannWolfram DoehnerNadja ScherbakovHarald HeideckePetra ReinkeHans-Dieter VolkPatricia GrabowskiInfection-triggered disease onset, chronic immune activation and autonomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) point to an autoimmune disease directed against neurotransmitter receptors. We had observed elevated autoantibodies against ß2 adrenergic receptors, and muscarinic 3 and 4 acetylcholine receptors in a subset of patients. Immunoadsorption (IA) was shown to be effective in removing autoantibodies and improve outcome in various autoimmune diseases.10 patients with post-infectious CFS/ME and elevated ß2 autoantibodies were treated with IA with an IgG-binding column for 5 days. We assessed severity of symptoms as outcome parameter by disease specific scores. Antibodies were determined by ELISA and B cell phenotype by flow cytometry.IgG levels dropped to median 0.73 g/l (normal 7-16 g/l) after the 4th cycle of IA, while IgA and IgM levels remained unchanged. Similarly, elevated ß2 IgG antibodies rapidly decreased during IA in 9 of 10 patients. Also 6 months later ß2 autoantibodies were significantly lower compared to pretreatment. Frequency of memory B cells significantly decreased and frequency of plasma cells increased after the 4th IA cycle. A rapid improvement of symptoms was reported by 7 patients during the IA. 3 of these patients had long lasting moderate to marked improvement for 6-12+ months, 2 patients had short improvement only and 2 patients improved for several months following initial worsening.IA can remove autoantibodies against ß2 adrenergic receptor and lead to clinical improvement. B cell phenotyping provides evidence for an effect of IA on memory B cell development. Data from our pilot trial warrants further studies in CFS/ME.http://europepmc.org/articles/PMC5854315?pdf=render |
| spellingShingle | Carmen Scheibenbogen Madlen Loebel Helma Freitag Anne Krueger Sandra Bauer Michaela Antelmann Wolfram Doehner Nadja Scherbakov Harald Heidecke Petra Reinke Hans-Dieter Volk Patricia Grabowski Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE |
| title | Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. |
| title_full | Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. |
| title_fullStr | Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. |
| title_full_unstemmed | Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. |
| title_short | Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. |
| title_sort | immunoadsorption to remove ss2 adrenergic receptor antibodies in chronic fatigue syndrome cfs me |
| url | http://europepmc.org/articles/PMC5854315?pdf=render |
| work_keys_str_mv | AT carmenscheibenbogen immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT madlenloebel immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT helmafreitag immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT annekrueger immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT sandrabauer immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT michaelaantelmann immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT wolframdoehner immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT nadjascherbakov immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT haraldheidecke immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT petrareinke immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT hansdietervolk immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme AT patriciagrabowski immunoadsorptiontoremoveß2adrenergicreceptorantibodiesinchronicfatiguesyndromecfsme |